Abstract Introduction Type 2 diabetes (T2D) management has reached a point where not
only optimal glycaemic control is necessary, but also additional interventions with proven …

Background: Semaglutide is a recently approved glucagon-like peptide-1 receptor agonist.
Several trials reported the protective effect of injectable semaglutide on cardiovascular (CV) …

Aim To describe the design of the SOUL trial (Semaglutide cardiOvascular oUtcomes triaL)
and the baseline clinical data of its participants. Materials and methods In SOUL, the effects …

Background Semaglutide is a glucagon-like peptide-1 (GLP-1) analog treatment for type 2
diabetes (T2D) available in subcutaneous (sc) and oral formulations. Two cardiovascular …

Abstract Background Cardiovascular outcome trials (CVOTs) are conducted on a
background of standard of care including metformin. These analyses sought to determine …

Cardiovascular events related to atherosclerosis are responsible for high morbidity and
mortality among patients with type 2 diabetes. Improvement in care, especially in early …

Background The SUSTAIN 6 trial demonstrated that once-weekly semaglutide (0.5 and 1.0
mg) significantly reduced major adverse cardiovascular (CV) events (MACE) vs placebo in …

Methods People with T2D initiated on oral semaglutide in secondary care diabetes clinics at
two hospital sites in Wales (United Kingdom) were included. Data were collected on reasons …

Background: Cardiovascular morbidity and mortality are a major burden in patients with type
2 diabetic mellitus. In a landmark study, semaglutide (an injectable glucagon like peptide-1 …

Methods Data were pooled for participants with type 2 diabetes and established CV disease
or high CV risk in the SUSTAIN 6 and PIONEER 6 trials. Participants received sc …